Core Viewpoint - The company, Innovent Biologics (01801), has seen its stock price increase by over 5%, currently trading at HKD 90.1, following the announcement of a strategic partnership with Eli Lilly to advance global R&D in oncology and immunology [1] Group 1: Strategic Partnership - Innovent Biologics has entered into its seventh strategic collaboration with Eli Lilly, focusing on innovative drug development in oncology and immunology [1] - The agreement includes an upfront payment of USD 350 million, with potential milestone payments totaling up to approximately USD 8.5 billion based on various development, regulatory, and commercialization milestones [1] - The partnership will also allow Innovent to receive a share of sales from related products in markets outside Greater China, enhancing its revenue potential [1] Group 2: Financial Implications - The upfront payment of USD 350 million is expected to be received soon, which will effectively cover the company's future overseas clinical investments [1] - Haitong International believes that the upfront and milestone payments will strengthen Innovent's financial safety net, while the sales share will provide long-term benefits from global market growth [1] - Goldman Sachs considers the current stock price undervalued, given the high implied weighted average cost of capital (12%), and has assigned a "Buy" rating with a target price of HKD 102.85 [1] Group 3: Competitive Positioning - The collaboration focuses on oncology and immunology, which aligns with Innovent's existing core pipeline, including IBI363 (PD1/IL2) and IBI343 (CLDN18.2ADC), enhancing overall competitiveness [1]

Core Viewpoint - CITIC Securities maintains a "Buy" rating for Innovent Biologics (01801), projecting revenues of 11.806 billion yuan, 15.382 billion yuan, and 21.092 billion yuan for 2025-2027, respectively, with a DCF valuation indicating a fair market value of 221.5 billion HKD and a target price of 129.61 HKD [1] Group 1 - The company has established a significant presence in the oncology sector, with high-value clinical products expected to enhance revenue and reduce marginal costs [1] - In non-oncology sectors, the company has made extensive investments in metabolism, autoimmune diseases, and ophthalmology, with competitive and advanced products both launched and in development [1] Group 2 - On October 22, Innovent Biologics entered a global strategic partnership with Takeda Pharmaceutical, which will pay 1.2 billion USD upfront, including a strategic equity investment of 100 million USD at a subscription price of 112.56 HKD per share, representing a 20% premium over the weighted average share price of the past 30 trading days [1] - The total value of the collaboration could reach 11.4 billion USD, with Innovent Biologics and Takeda jointly developing IBI363 (PD-1/IL-2α-bias) [1] - Innovent Biologics granted Takeda exclusive rights for IBI343 (CLDN18.2ADC) outside Greater China and exclusive options for IBI3001 (EGFR/B7H3ADC) outside Greater China [1]